GSK Glaxo Smith

Infanrix hexa is a hexavalent combination vaccine manufactured by GlaxoSmithKline Biologicals S.A. that provides immunization against six infectious diseases: diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b. The vaccine is administered as an adsorbed injection and belongs to the antiinfectives for systemic use therapeutic class (ATC J07). The program completed Phase 3 clinical development, with the latest milestone recorded on 2 January 2020. Infanrix hexa received European Medicines Agency (EMA) approval on 12 February 2026, with GlaxoSmithKline Biologicals S.A. designated as the marketing authorization holder under EMEA/H/C/000296. The vaccine addresses the clinical need for simplified immunization schedules by combining multiple antigens into a single injection, reducing the number of injections required during childhood vaccination programs.

Infanrix hexa addresses a significant unmet medical need in pediatric immunization by consolidating six separate vaccine antigens into a single formulation. This combination approach reduces the injection burden on infants and young children while maintaining immunogenicity against all six target pathogens. The vaccine is particularly relevant in healthcare systems seeking to improve vaccination compliance and reduce healthcare provider workload during routine immunization visits. The poliomyelitis indication reflects ongoing global efforts to maintain and strengthen immunity against poliovirus, especially in regions with lower baseline population immunity. Commercially, hexavalent vaccines represent a mature but essential segment of the pediatric immunization market, with established demand across developed and developing healthcare systems. The competitive landscape includes other combination vaccines such as Hexyon, which targets similar indications. Infanrix hexa's market relevance is sustained by the universal requirement for childhood vaccination programs and the clinical preference for combination formulations that simplify immunization schedules and improve parental compliance.

Drug Class: Combination vaccine (hexavalent)

Modality: Monoclonal antibody (as classified in source data)

Active Ingredients: Diphtheria (D), tetanus (T), pertussis (acellular, component) (PA), hepatitis B (recombinant DNA) (HBV), poliomyelitis (inactivated) (IPV), and Haemophilus influenzae type-b (Hib) conjugate vaccine (adsorbed)

Route of Administration: Not yet disclosed

Therapeutic Class: Antiinfectives for systemic use (ATC J07)

Mechanism of Action: Not yet disclosed

Target: Not yet disclosed

Related Therapies: Other hexavalent or pentavalent combination vaccines including Hexyon; monovalent or bivalent vaccines targeting individual antigens (diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Haemophilus influenzae type b)

First Approval: European Union, 12 February 2026

Patent Status: Not yet disclosed

European Union: Infanrix hexa received marketing authorization from the European Medicines Agency on 12 February 2026. GlaxoSmithKline Biologicals S.A. is the marketing authorization holder. The product is registered under EMEA/H/C/000296. Full product information is available on the EMA website at https://www.ema.europa.eu/en/medicines/human/EPAR/infanrix-hexa.

United States (FDA): Regulatory status not yet disclosed.

Japan (PMDA): Regulatory status not yet disclosed.

China (NMPA): Regulatory status not yet disclosed.

Other Jurisdictions: Regulatory status in additional markets not yet disclosed.

Strategic Positioning: GlaxoSmithKline's Infanrix hexa represents a mature, established vaccine in the pediatric immunization portfolio. The 2026 EMA approval confirms regulatory acceptance of the hexavalent formulation, supporting continued market presence in European healthcare systems. The Phase 3 completion in early 2020 preceded the formal EMA approval by approximately six years, suggesting a protracted regulatory review or potential additional data generation requirements.

Competitive Implications: The hexavalent vaccine market remains competitive but essential. Infanrix hexa's primary competitor, Hexyon, offers similar immunization coverage. Differentiation is likely based on manufacturing consistency, safety profile, immunogenicity data, and healthcare system adoption patterns rather than novel mechanisms. The broader vaccine landscape includes numerous approved alternatives targeting individual or smaller combinations of pathogens, providing healthcare systems with multiple immunization strategy options.

Future Catalysts: Regulatory approvals in additional jurisdictions (FDA, PMDA, NMPA) would expand market access. Label expansions or indication extensions are possible but not yet disclosed. Potential future developments include formulation improvements, additional combination antigens, or expanded age indications.

Expected Milestones: No future milestones are currently disclosed. Monitoring for regulatory submissions in non-EU jurisdictions, clinical trial initiations for label expansions, or manufacturing capacity announcements would provide additional intelligence.